-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
The Perfect Medical Health Management Limited (HKG:1830) Analyst Just Boosted Their Forecasts By A Notable Amount
The Perfect Medical Health Management Limited (HKG:1830) Analyst Just Boosted Their Forecasts By A Notable Amount
Celebrations may be in order for Perfect Medical Health Management Limited (HKG:1830) shareholders, with the covering analyst delivering a significant upgrade to their statutory estimates for the company. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with the analyst modelling a real improvement in business performance.
Following the upgrade, the latest consensus from Perfect Medical Health Management's solo analyst is for revenues of HK$2.0b in 2023, which would reflect a major 49% improvement in sales compared to the last 12 months. Per-share earnings are expected to soar 68% to HK$0.41. Prior to this update, the analyst had been forecasting revenues of HK$1.6b and earnings per share (EPS) of HK$0.28 in 2023. There has definitely been an improvement in perception recently, with the analyst substantially increasing both their earnings and revenue estimates.
View our latest analysis for Perfect Medical Health Management
SEHK:1830 Earnings and Revenue Growth August 14th 2022With these upgrades, we're not surprised to see that the analyst has lifted their price target 42% to HK$11.90 per share.
Of course, another way to look at these forecasts is to place them into context against the industry itself. The analyst is definitely expecting Perfect Medical Health Management's growth to accelerate, with the forecast 49% annualised growth to the end of 2023 ranking favourably alongside historical growth of 9.4% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 17% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Perfect Medical Health Management is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away from this upgrade is that the analyst upgraded their earnings per share estimates for this year, expecting improving business conditions. They also upgraded their revenue estimates for this year, and sales are expected to grow faster than the wider market. Given that the consensus looks almost universally bullish, with a substantial increase to forecasts and a higher price target, Perfect Medical Health Management could be worth investigating further.
Still, the long-term prospects of the business are much more relevant than next year's earnings. At least one analyst has provided forecasts out to 2025, which can be seen for free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
庆祝活动可能是为了完美医疗健康管理有限公司(HKG:1830)股东,采访分析师大幅上调了他们对公司的法定估计。共识估计表明,投资者预计法定收入和每股收益将大幅增长,分析师将对企业业绩的实际改善进行建模。
升级后,完美医疗健康管理的独立分析师的最新共识是2023年收入将达到20亿港元,这将反映出与过去12个月相比,销售额有49%的重大改善。每股盈利料大增68%至0.41港元。在此更新之前,分析师一直预测2023年收入为16亿港元,每股收益(EPS)为0.28港元。最近,人们的看法肯定有所改善,分析师大幅提高了他们的收益和收入预期。
查看我们的最新分析,完善医疗健康管理
联交所:1830盈利及收入增长2022年8月14日在这些上调后,我们并不意外地看到,分析师将目标价上调了42%,至每股11.90港元。
当然,看待这些预测的另一种方式是将它们放在与行业本身相反的背景下。这位分析师肯定预计完美医疗健康管理公司的增长将会加快,截至2023年底的预测年化增长率为49%,与过去五年9.4%的历史年增长率相比是有利的。相比之下,同行业的其他公司预计每年收入增长17%。考虑到收入的预期加速增长,完美医疗健康管理公司的增长速度预计将远远快于其行业,这一点非常明显。
底线
这次升级最重要的一点是,分析师上调了今年的每股收益预期,预计商业状况会有所改善。他们还上调了今年的收入预期,预计销售额的增长速度将快于更广泛的市场。鉴于共识看起来几乎普遍看涨,大幅上调预测和更高的价格目标,完美的医疗健康管理可能值得进一步研究。
尽管如此,该业务的长期前景比明年的收益更具相关性。至少有一位分析师提供了对2025年的预测,这可以在我们的平台上免费看到。
搜索有趣的公司的另一种方式可能是到达拐点是跟踪管理层是在买入还是在卖出,我们的免费内部人士正在收购的成长型公司名单。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧